Search results for "Insulin"

showing 10 items of 1360 documents

Diabetes mellitus secondary to Cushing's disease

2018

Associated with important comorbidities that significantly reduce patients’ overall wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of endogenous hypercortisolism. Glucocorticoid excess can lead to diabetes, and although its prevalence is probably underestimated, up to 50% of patients with CD have varying degrees of altered glucose metabolism. Fasting glycemia may nevertheless be normal in some patients in whom glucocorticoid excess leads primarily to higher postprandial glucose levels. An oral glucose tolerance test should thus be performed in all CD patients to identify glucose metabolism abnormalities. Since diabetes mellitus (DM) is a consequence of cortis…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologyCarbohydrate metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineInsulin resistanceCortisol-lowering medication; Cushing's disease; Diabetes; Glucocorticoids; Insulin resistance; Endocrinology Diabetes and MetabolismEndocrinologyInternal medicineDiabetes mellitusmedicineGlucocorticoidslcsh:RC648-665business.industryDiabetesInsulin resistanceCushing's diseaseCushing’s diseasemedicine.diseaseDiabetes and MetabolismEndocrinologyPostprandialCortisol-lowering medicationCushing's diseasePituitary surgerybusinessGlucocorticoidmedicine.drug
researchProduct

The diabetogenic action of statins — mechanisms and clinical implications

2015

Treatment with statins has transformed primary and secondary prevention of cardiovascular disease (CVD), including thrombotic stroke. Evidence-based data demonstrate the benefits and safety of statin therapy and help to guide clinicians in the management of populations at high risk of CVD. Nevertheless, clinical trials, meta-analyses and observational studies highlight a 10-12% increase in new-onset diabetes mellitus (NODM) among patients receiving statins. The risk further increases with intensive therapy and among individuals with known risk factors for NODM. Mechanisms underpinning this effect are not yet fully understood; however, Mendelian randomization studies suggest that they are re…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseType 2 diabetesIn Vitro Techniques030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistancePharmacotherapyRisk FactorsInsulin-Secreting CellsDiabetes mellitusMendelian randomizationSecondary PreventionAnimalsHumansMedicinecardiovascular diseasesIntensive care medicinebusiness.industrynutritional and metabolic diseasesFeeding BehaviorMendelian Randomization Analysismedicine.diseaseClinical trialDiabetes Mellitus Type 2Cardiovascular DiseasesPhysical therapyHydroxymethylglutaryl CoA ReductasesObservational studyHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessRisk Reduction BehaviorNature Reviews Endocrinology
researchProduct

Insulin Resistance and the Cardiometabolic Syndrome in HIV Infection

2009

Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of HIV-positive patients. However, long-term adverse effects of this therapy include dyslipidemia, insulin resistance (IR), changes in body fat distribution (lipodystrophy), and cardiometabolic syndrome (CMS). IR in HIV-positive patients does not seem to represent a significant independent risk factor for the development of cardiovascular disease; nevertheless, the association with other metabolic complications (dyslipidemia, fat redistribution) and CMS may increase the risk of type 2 diabetes and cardiovascular disease. The use of nucleoside analogue reverse transcriptase inhibitors is associated with the …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHIV InfectionsType 2 diabetesGastroenterologyInsulin resistanceAntiretroviral Therapy Highly ActiveDiabetes mellitusInternal medicineInternal MedicinemedicineHumansRisk factorMetabolic Syndromebusiness.industrymedicine.diseaseMetforminEndocrinologyCardiovascular DiseasesInsulin ResistanceLipodystrophyCardiology and Cardiovascular MedicinebusinessRosiglitazoneDyslipidemiamedicine.drugJournal of the CardioMetabolic Syndrome
researchProduct

Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity

2004

OBJECTIVE: We investigated the possible causes of diabetes in a young child who presented with hyperglycemia associated with severe hypertriglyceridemia (>166 mmol/l), hypercholesterolemia (>38 mmol/l) and fasting chilomicrons. RESULTS: The patient did not have any of the HLA and autoantibody markers typically associated with type 1 diabetes. A glucose clamp failed to demonstrate insulin resistance (peripheral glucose utilization rate (M)=4.3 mg/kg per min) and there was no family history of type 2 diabetes or maturity onset diabetes in youth. Both fasting and stimulated C-peptide levels, including those in response to i.v. glucagon, were below the limit of detection. This is consiste…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercholesterolemiaAutoimmunityType 2 diabeteschylomicronemia diabetes young girl autoimmunityGlucagonIslets of LangerhansLipoprotein lipase deficiencyEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusChylomicronsmedicineHumansChildAutoantibodiesHypertriglyceridemiaType 1 diabetesC-Peptidebusiness.industryHypertriglyceridemiaFastingGeneral MedicineGlucose clamp techniqueGlucagonmedicine.diseaseLipoprotein LipaseDiabetes Mellitus Type 1EndocrinologyHyperglycemiaGlucose Clamp TechniqueFemalelipids (amino acids peptides and proteins)businessEuropean Journal of Endocrinology
researchProduct

Real‐world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon‐…

2020

Abstract Aim To assess the impact of the timing of initiating both basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on reaching glycaemic control targets over 6 and 12 months in people with type 2 diabetes (T2D) uncontrolled on oral antihyperglycaemic drugs with an HbA1c of 9% or higher. Methods This retrospective cohort study assessed the impact of the timing of initiating both basal insulin and GLP‐1 RA therapies on reaching glycaemic targets (HbA1c < 7% and <8%, and ≥1% and ≥2% HbA1c reduction) over 12 months in people with markedly uncontrolled T2D (HbA1c ≥ 9%) on oral antihyperglycaemic drugs identified on the Optum Humedica database (electronic medical records; …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismInsulins030209 endocrinology & metabolismGlycemic ControlType 2 diabetes030204 cardiovascular system & hematologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyGLP‐1 analogueInternal medicinecohort studyInternal MedicineHumansHypoglycemic AgentsInsulinMedicinebasal insulinRetrospective StudiesGlycated Hemoglobindatabase researchbusiness.industryMedical recordHazard ratioRetrospective cohort studyOriginal Articlesmedicine.diseaseGlucagon-like peptide-1Confidence intervalglycaemic controlDiabetes Mellitus Type 2Pharmaceutical PreparationsCohortOriginal Articletype 2 diabetesbusinessCohort studyDiabetes, Obesity and Metabolism
researchProduct

Comment on: Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injecti…

2020

medicine.medical_specialtyEndocrinology Diabetes and MetabolismMEDLINEGermanEndocrinologyInsulin Infusion SystemsInternal medicineInternal MedicineMedicineHumansHypoglycemic AgentsInsulinRegistriesInsulin injectionAgedAged 80 and overType 1 diabetesbusiness.industrymedicine.diseaselanguage.human_languageSubcutaneous insulinDiabetes Mellitus Type 1AustrialanguagebusinessOlder peopleDiabetic medicine : a journal of the British Diabetic Association
researchProduct

Genetic and environmental aspect of polycystic ovary syndrome.

2004

Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome determined in most patients by the association of two main factors: hyperandrogenism and insulin resistance. These characters are probably independent of each other and seem to be inherited by several different mechanisms. In some patients homozygous gene alteration has been found but in most patients PCOS seems to be determined by the association of gene polymorphisms that are common in the general population but alone are unable to determine phenotypic consequences. Alteration of genes that regulate the initial steps of ovarian steroidogenesis is probably the main causal factor of hyperandrogenism. Insulin resistance may be the …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationBiologyEatingEndocrinologyInsulin resistanceInternal medicineInsulin receptor substratemedicineHumansGenetic Predisposition to DiseaseObesityeducationGeneeducation.field_of_studyHyperandrogenismmedicine.diseaseObesityPhenotypePolycystic ovaryEndocrinologyFemaleInsulin ResistanceEnergy MetabolismHyperandrogenismPolycystic Ovary SyndromeJournal of endocrinological investigation
researchProduct

Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality.

2014

High-density lipoprotein (HDL) particles are highly complex polymolecular aggregates capable of performing a remarkable range of atheroprotective functions. Considerable research is being performed throughout the world to develop novel pharmacologic approaches to: (1) promote apoprotein A-I and HDL particle biosynthesis; (2) augment capacity for reverse cholesterol transport so as to reduce risk for the development and progression of atherosclerotic disease; and (3) modulate the functionality of HDL particles in order to increase their capacity to antagonize oxidation, inflammation, thrombosis, endothelial dysfunction, insulin resistance, and other processes that participate in arterial wal…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismRVX 208BiologyBioinformaticschemistry.chemical_compoundEndocrinologyInsulin resistanceHigh-density lipoproteinInternal medicinemedicineHumansEndothelial dysfunctionLiver X receptorDyslipidemiasTherapies InvestigationalReverse cholesterol transportCholesterol HDLGenetic Therapymedicine.diseaseUp-RegulationEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Farnesoid X receptorLipoproteinBest practiceresearch. Clinical endocrinologymetabolism
researchProduct

From obesity to Alzheimer's disease through insulin resistance

2021

Alzheimer's disease is one of the most frequent forms of dementia. It is a progressive neurodegenerative disease, characterized by presence of amyloid plaques and neurofibrillary tangles in the brain. Obesity is regarded as abnormal fat accumulation with deleterious impact on human health. There is full scientific evidence that obesity and the metabolic comorbidities (e.g., insulin resistance, hyperglycaemia, and type 2 diabetes) are related to Alzheimer's disease and likely in the causative pathway. Numerous studies have identified several overlapping neurodegenerative mechanisms, including oxidative stress, mitochondrial dysfunction, and inflammation. In this review, we present how obesit…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismType 2 diabetesmedicine.disease_causeEndocrinologyInsulin resistanceDownregulation and upregulationAlzheimer DiseaseInternal medicineDiabetes mellitusInternal MedicinemedicineHumansDementiaObesityNeurodegenerationInflammationbusiness.industryNeurodegenerationBrainInsulin resistanceAlzheimer's diseasemedicine.diseaseEndocrinologyDiabetes Mellitus Type 2LipotoxicitybusinessOxidative stressJournal of Diabetes and its Complications
researchProduct

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month…

2017

INTRODUCTION: Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes. METHODS: We selected 105 diabetic outpatients who were treated with liraglutide for at least 48 months as an add-on therapy to metformin alone (group A, n = 52) or insulin secretagogues (group B, n = 53) from diagnosis time. RESULTS: Altho…

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyGastroenterologySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineInternal MedicinemedicineGlycemicFramingham Risk Scorebusiness.industryLiraglutideBrief ReportInsulinDiabetesLiraglutideCardiovascular riskmedicine.diseaseliraglutide diabetesMetforminEndocrinologyBlood pressureVisceral adipositybusinessmedicine.drug
researchProduct